Although PROTACS should be considered useful against cancers with mutant p53, another interesting compound, YX-02-030, holds promise against cancers irrespective of their p53 status, since it activates p73, a homolog of p53, which partially compensates for the loss of functional p53 [97]. Here, TP53 is linked to cancer.